Qiagen N : announces adjustment of conversion price under its US$500,000,000 Convertible Bonds due 2031
QIAGEN N.V. has announced an adjustment to the conversion price of its US$500,000,000 Convertible Bonds due 2031. This adjustment, effective July 7, 2026, sets the new conversion price at US$63.1914. The change was made to reflect a cash dividend payment of US$0.35 per ordinary share, approved at the Annual General Meeting on June 24, 2026, and payable on July 14, 2026.
Qiagen N.V. focuses on diagnostics growth and US exposure
Qiagen N.V. is strategically expanding its molecular diagnostics and sample preparation portfolio, emphasizing recurring consumables revenue and growth in the US healthcare and research markets. The company's business model relies on consumables and instrument placements for clinical, academic, and pharmaceutical customers, with significant sales generated in the US from hospital and reference labs, biopharmaceutical companies, and research institutions. Qiagen's focus on infectious disease testing, oncology, and genomic research, along with its cartridge-based platforms, aims to streamline lab workflows and ensure reliable molecular assays.
Qiagen N.V. highlights its role in global diagnostics as investors track long-term growth
Qiagen N.V. is a biotechnology group specializing in sample and assay technologies crucial for molecular diagnostics and life science research. The company offers integrated solutions including consumables, instruments, and software to laboratories, supporting standardized workflows for clinical and research applications. Investors are monitoring Qiagen's position in the long-term growth trends of healthcare spending and the adoption of molecular technologies.
Qiagen N.V. highlights molecular diagnostics growth as investors eye global health demand
Qiagen N.V. is emphasizing its strong position in molecular diagnostics and life-science tools, with its business model benefiting from sustained demand in healthcare and research. The company's growth is driven by recurring revenue from test kits and consumables used on its instrument platforms in clinical and research laboratories worldwide. Investors are focusing on the long-term expansion of molecular testing and genomic analysis, which provides diversification across different budget cycles and funding environments.
How Investors Are Reacting To Qiagen (QGEN) Joining The Russell 1000 Dynamic Index
Qiagen N.V. (QGEN) has been added to the Russell 1000 Dynamic Index, increasing its visibility among institutional investors but not fundamentally changing its near-term outlook. The company recently cut its 2026 net sales growth guidance, placing more emphasis on new product launches and higher-margin platforms to offset slower growth. While some analysts have more optimistic revenue and earnings forecasts, the index inclusion primarily impacts fund trading strategies rather than immediate operational changes for Qiagen.
Qiagen N.V. highlights its role in molecular diagnostics as investors track the stock
Qiagen N.V. is presented as a key player in sample preparation and molecular diagnostics, offering solutions for transforming biological materials into molecular information. The company's stock allows investors exposure to the life science tools segment, with demand driven by trends in molecular research, personalized medicine, infectious disease testing, and oncology. Qiagen's business focuses on streamlining workflows from sample collection to analysis, providing integrated solutions including instruments, consumables, and software.
Price to earnings forward of Qiagen N.V. – NYSE:QGEN
This article provides the "Price to earnings forward" value for Qiagen N.V. (NYSE: QGEN). It lists the company's stock exchange listing and links to various financial data, news, and community sections on TradingView, indicating it's a data point within a larger financial platform.
Qiagen N.V. highlights its diagnostics reach as investors weigh long-term demand
Qiagen N.V. is attracting investor attention due to its significant role in molecular diagnostics and sample preparation technology. The company's business model, which combines instrument sales with recurring revenue from consumables, positions it strongly for long-term demand in healthcare and research, driven by factors like an aging population and advancements in precision medicine. Its diverse portfolio and established presence in clinical diagnostics and life science research underscore its potential for sustained growth amidst evolving market dynamics.
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG
QIAGEN N.V. (QGEN) has released a voting rights announcement in accordance with Article 40, Section 1 of the WpHG. The notification, issued by the AFM on July 1, 2026, details a transaction dated June 25, 2026, involving Goldman Sachs Group Inc., The, and various types of shares, voting rights, and capital interests in QIAGEN N.V., amounting to a total holding of 2.90% for both capital interest and voting rights for Goldman Sachs.
Release according to Article 40, Section 1 of the WpHG
This article reports a public release by QIAGEN N.V. regarding a voting rights announcement, as informed by the AFM. Goldman Sachs Group Inc., The, is the person obliged to notify, concerning various types of shares, swaps, and options in QIAGEN N.V., reflecting both potential and real capital interests and voting rights. The total holding for capital interest and voting rights is reported at 2.90%.
Qiagen N.V. highlights diagnostics role amid steady investor interest
Qiagen N.V. is presented as a key diagnostics supplier, noted for its recurring revenue model, global lab presence, and focus on molecular testing. The company provides a comprehensive ecosystem of instruments, consumables, and software for molecular diagnostics and life science research, covering areas from infectious disease testing to oncology and genetic analysis. With a strong emphasis on workflow integration and an expanding test menu, Qiagen serves clinical, research, and applied markets, ensuring consistent demand for its innovative solutions.
QGEN - Qiagen NV Short Interest
This article provides comprehensive financial data for Qiagen NV (QGEN), including its short interest, key financial ratios, performance metrics, and analyst recommendations. It details various aspects such as market capitalization, earnings per share, sales growth, insider and institutional ownership, and price performance over different periods.
QGEN - Qiagen NV Earnings
The article provides a detailed financial overview of Qiagen NV (QGEN), including its latest stock performance, key financial metrics, valuation ratios, and dividend information. It also lists insider and institutional ownership, profitability ratios, and various performance indicators over different periods.
Qiagen N.V. outlines long-term growth drivers as diagnostics demand expands
Qiagen N.V. is strategically positioning its diagnostics and sample preparation business for sustained growth by emphasizing recurring consumables revenue and meeting global laboratory demand. The company, which specializes in sample and assay technologies for molecular diagnostics and life sciences research, focuses on providing tools for analyzing genetic material. Its business model integrates capital equipment with high-margin consumables and software, serving clinical diagnostics, applied testing, and academic research sectors globally.
Is Qiagen (QGEN) Undervalued Following Its Index Addition And QIAcuity Expansion?
Qiagen (QGEN) has been added to the Russell 1000 Dynamic Index and expanded its QIAcuity digital PCR ecosystem, aiming for increased visibility and a more extensive product offering. Despite recent short-term share price gains, its year-to-date and one-year returns are down, prompting questions about whether its current trading price represents an undervalued opportunity. An analysis suggests Qiagen is approximately 9.5% undervalued, with a fair value of $43.96, based on expected revenue growth and improved margins.
QIAGEN NV Actuals & Estimates (TURQUOISE:QIAD)
This article provides an overview of QIAGEN NV (QIAD) on the TURQUOISE exchange, including its financial actuals, analyst estimates, and key performance indicators. It details historical stock prices, upcoming earnings dates, latest quarterly earnings and revenue, net income, dividend yield, employee count, and EBITDA. The content emphasizes that this information is for reference and not investment advice, encouraging users to conduct their own research.
Qiagen N.V. refines diagnostics portfolio, shares backed by long-term strategy
Qiagen N.V. is strategically refining its molecular diagnostics and sample technologies portfolio through targeted investments and acquisitions. The company emphasizes its long-term positioning in global healthcare and life sciences, focusing on integrated workflows, infectious disease testing, oncology, and genetic screening. Qiagen's shares are listed on the NYSE, reflecting its role as a key player in the competitive diagnostics market.
Price to sales forward of Qiagen N.V. – NYSE:QGEN
This page from TradingView provides financial information for Qiagen N.V. (NYSE:QGEN), specifically focusing on its forward price-to-sales ratio. The content indicates that while the company's stock is listed on the New York Stock Exchange, no current trade data is available. The page is designed to offer a quick financial overview for investors interested in QGEN.
QIAGEN NV Actuals & Estimates (VIE:QGE4)
This article provides an "Actuals & Estimates" overview for QIAGEN NV (QGE4) on the Vienna Stock Exchange, detailing its current stock price, trading performance, analyst forecasts, and historical highs and lows. It also includes key financial metrics such as market capitalization, earnings, revenue, net income, EBITDA, and dividend yield, along with the next earnings report date.
Enterprise value to EBIT forward of Qiagen N.V. – NYSE:QGEN
This article provides financial data for Qiagen N.V. (NYSE:QGEN), focusing on its enterprise value to EBIT forward. It seems to be a financial data page from TradingView, presenting key metrics for investors and analysts interested in the company's valuation.
QGEN Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for QIAGEN NV (QGEN) stock for 2027, based on analysis from 16 analysts. It details the current stock price, market capitalization, historical highs and lows, and upcoming earnings reports. The report also includes financial metrics like revenue, net income, EBITDA, and dividend information, along with frequently asked questions about QGEN.
Qiagen NV Annual Shareholders Meeting Transcript
This article provides the transcript of Qiagen NV's Annual Shareholders Meeting held on June 24, 2026. The meeting was chaired by Stephen Raskowski, and attended by members of the Supervisory and Managing Boards, along with auditors. The transcript details the opening remarks and procedural details for the meeting.
Is Qiagen's (QGEN) Digital PCR Expansion Quietly Redefining Its Competitive Moat in Biopharma Tools?
QIAGEN has expanded its QIAcuity digital PCR ecosystem with new gene expression assays, high-multiplex PCR kits, and enhanced automation options for biopharma users. This strategic move aims to deepen the integration of its tools and standardize high-throughput workflows, thereby strengthening Qiagen's long-term competitive position in the life sciences sector. While unlikely to immediately impact 2026 guidance, the expansion reinforces the company's innovation pipeline and supports its core investment case as a scaled diagnostics provider.
PTA-DD: QIAGEN N.V.: Managers' transactions announcement according to article 19 MAR
This article details a manager's transaction at QIAGEN N.V., specifically the vesting of Restricted Stock Units for Metin Colpan, a former member of the administrative or supervisory body. Colpan received 17,726 common shares through this automated vesting process, followed by a net settlement of 8,905 common shares after expenses. The transaction took place on June 24, 2026, outside a trading venue.
QGEN Forecast — Price Target — Prediction for 2027
This article provides a detailed forecast and financial overview for Qiagen N.V. (QGEN) stock, including analyst price targets, historical performance, and key financial metrics. It highlights the current stock price, recent volatility, market capitalization, and upcoming earnings reports, offering insights into its investment potential.
Enterprise value to EBITDA forward of Qiagen N.V. – NYSE:QGEN
This article presents the Enterprise Value to EBITDA forward for Qiagen N.V. (NYSE: QGEN). The financial data is provided by ICE Data Services and FactSet, with SEC filings from Quartr. The content mainly consists of navigational elements and copyright information.
Is Qiagen's (QGEN) Digital PCR Expansion Quietly Redefining Its Competitive Moat in Biopharma Tools?
QIAGEN has expanded its QIAcuity digital PCR ecosystem with new assays, kits, software, and automation options, aiming to make digital PCR more accessible for life sciences and biopharma. This move reinforces Qiagen's strategy to deepen instrument utilization through higher-multiplex, automated workflows, modestly strengthening its portfolio. While this expansion may boost long-term relevance in regulated labs, short-term growth headwinds and underwhelming share price performance remain key concerns for investors.
Release according to Article 40, Section 1 of the WpHG
QIAGEN N.V. has released a notification regarding voting rights, as informed by the AFM. The notification details a transaction on June 17, 2026, involving Goldman Sachs Group Inc. as the notifying party, outlining various types of shares, voting rights, and capital interests distributed indirectly through several Goldman Sachs entities.
Barclays Maintains Qiagen NV(QGEN.US) With Hold Rating, Maintains Target Price $38
Barclays has reiterated its Hold rating on Qiagen NV (QGEN.US), keeping its target price steady at $38. This indicates the firm's continued assessment of Qiagen's stock performance.
Qiagen Raised to Overweight From Equal-Weight by Morgan Stanley
Morgan Stanley has upgraded its rating for Qiagen from Equal-Weight to Overweight. This change in rating indicates a more positive outlook from the financial institution regarding Qiagen's stock performance.
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG
QIAGEN N.V. has released a notification regarding voting rights, as informed by the AFM on June 23, 2026. Goldman Sachs Group Inc. has disclosed various holdings in QIAGEN N.V. shares, swaps, call options, warrants, and convertible bonds. The total capital interest and voting rights held by Goldman Sachs Group Inc. indirectly amounts to 3.33%.
Morgan Stanley Upgrades Qiagen NV(QGEN.US) to Buy Rating, Raises Target Price to $42
Morgan Stanley has upgraded Qiagen NV (QGEN.US) to a Buy rating and increased its target price to $42. This indicates a positive outlook from the firm regarding the company's future stock performance.
Qiagen NV: QIAGEN N.V. - Share Consolidation/Cash Distribution Option Symbol: QGEN New Symbol: QGEN1
The article announces a share consolidation and cash distribution option for Qiagen NV (Symbol: QGEN), resulting in a new symbol QGEN1. This change indicates a corporate action impacting the company's stock structure and potentially its trading.
QIAGEN Bets Big on Digital PCR with Major QIAcuity Ecosystem Expansion
QIAGEN has announced significant expansions to its QIAcuity digital PCR (dPCR) ecosystem, focusing on enhancing gene expression capabilities, broadening assay content, and standardizing workflows. These advancements aim to drive wider adoption of dPCR across life sciences and biopharmaceutical applications by offering higher sensitivity, precision, and multiplexing capabilities. The new additions include planned gene expression assay launches, a 12-plex RNA analysis kit, expanded cell and gene therapy quality control offerings, enhanced automated analysis software, and integration with Hamilton robotic systems for fully automated workflows.
Release according to Article 40, Section 1 of the WpHG
QIAGEN N.V. has released a voting rights announcement in accordance with Article 40, Section 1 of the WpHG, based on a notification from the AFM dated June 18, 2026. Goldman Sachs Group Inc., The, is identified as obliged to notify, with a transaction date of June 15, 2026, indicating various types of shares, call-options, warrants, and swaps held indirectly. The total capital interest and voting rights for Goldman Sachs amount to 2.87%.
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG
QIAGEN N.V. (QGEN) has released a voting rights announcement in accordance with Article 40, Section 1 of the WpHG, following a notification from the AFM on June 18, 2026. Goldman Sachs Group Inc., The, is the person obliged to notify, with various indirect holdings in QIAGEN N.V. shares, call options, warrants, convertible bonds, and swaps, amounting to a total capital interest and voting rights of 2.87%.
Goldman Sachs Reports 2.72% Voting Stake in Qiagen via AFM Filing
Goldman Sachs Group Inc. has disclosed a 2.72% voting stake in Qiagen, as reported by the Dutch financial regulator AFM. This stake primarily consists of indirect and potential interests through various financial instruments rather than direct equity. The disclosure highlights significant institutional interest in Qiagen, a Netherlands-based life sciences company, and provides insights for investors monitoring ownership shifts and derivative exposures.
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG
QIAGEN N.V. has released a voting rights announcement in accordance with Article 40, Section 1 of the WpHG, following notification from the AFM. The announcement details the holdings of Goldman Sachs Group Inc., The, in QIAGEN N.V. as of June 12, 2026, showing their capital and voting rights interest at 3.78%, predominantly held indirectly.
QIAGEN Bets Big on Digital PCR with Major QIAcuity Ecosystem Expansion
QIAGEN is significantly expanding its QIAcuity digital PCR (dPCR) ecosystem with new gene expression solutions, enhanced multiplexing capabilities, and advanced automation features. These additions, including new gene expression assays, 12-plex RNA analysis, and improved software for standardized reporting, aim to broaden dPCR's adoption across molecular biology, biopharmaceutical, and cell and gene therapy applications. The company highlights dPCR's increasing importance for higher sensitivity and precision, with over 3,200 QIAcuity placements worldwide and a growing number of scientific publications.
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG
QIAGEN N.V. announced a release according to Article 40, Section 1 of the WpHG, as informed by the AFM on June 16, 2026. This notification details the voting rights announcement from Goldman Sachs Group Inc., The, concerning various types of shares, call options, convertible bonds, warrants, and swaps in QIAGEN N.V. The distribution breakdown shows both potential and real capital and voting interests held indirectly by different Goldman Sachs entities.
Qiagen NV (QGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article details Qiagen NV's (QGEN) revenue breakdown by business segment and geographical region, based on fiscal year 2025 data. The company's revenue is primarily driven by "Consumables and Related Revenues," accounting for nearly 90%, with "Instrumentation" making up the rest. Geographically, the United States is the largest revenue contributor, followed by Europe & Middle East & Africa, and Asia, Pacific & Rest of the World.
Should Qiagen’s Expanded QIAcuity Automation Push Reshape the Core Investment Case for QGEN?
QIAGEN (QGEN) has expanded its QIAcuity digital PCR ecosystem with new gene expression assays, RNA kits, enhanced DNA testing, and upgraded analysis software, increasing automation for life sciences and biopharma labs. This move strengthens Qiagen's position in automated, high-throughput workflows, aligning with its core focus on automation, digital PCR, and syndromic testing. While these upgrades support long-term growth, investors need to consider near-term challenges such as trimmed sales guidance and persistent competition in digital PCR, as well as pressure on capital budgets.
Stifel reiterates Qiagen stock Hold rating after dPCR event
Stifel maintained a Hold rating and $36.00 price target for Qiagen NV following a digital PCR technology presentation, noting that despite the stock trading slightly above this target, InvestingPro data suggests the company is undervalued. Qiagen highlighted its QIAcuity digital PCR platform and upcoming "QIAcuity v2" instrument, aiming for double-digit growth by expanding clinical diagnostics and gene expression applications. The firm also revised Qiagen's 2028 revenue target and acknowledged recent financial news, including a Q1 revenue miss previously reported due to reduced immigrant testing.
Stifel reiterates Qiagen stock Hold rating after dPCR event
Stifel maintained a Hold rating and $36.00 price target for Qiagen NV following a digital PCR technology presentation, despite the stock trading slightly above this target. The company highlighted its QIAcuity digital PCR platform and new gene expression assays, with a next-generation "QIAcuity v2" in development. Stifel views digital PCR as a key growth driver, anticipating it will gradually replace quantitative PCR in high-sensitivity applications.
Qiagen NV (QGEN) Reiterated at Hold by Stifel Post QIAcuity digital PCR Deep-Dive
Stifel analyst Daniel Arias reiterated a Hold rating and a $36.00 price target on Qiagen NV (NYSE: QGEN) following a deep-dive into the company's QIAcuity digital PCR. The article provides this analyst rating but the full details of the analysis are behind a premium paywall.
Qiagen (NYSE:QGEN) Stock Forecast & Analyst Predictions
Qiagen (NYSE:QGEN) is forecast to grow earnings by 12.4% and revenue by 6.3% per annum, with EPS expected to increase by 11.9% annually. Analyst price targets have seen adjustments, with the latest average target decreased to US$48.46, representing a 44% upside from the current price. The company has also made significant announcements regarding expanded product portfolios, automation initiatives for its QIAcuity and QIAstat-Dx systems, and a proposed annual cash dividend increase.
QIAGEN Bets Big on Digital PCR with Major QIAcuity Ecosystem Expansion
QIAGEN is significantly expanding its QIAcuity digital PCR ecosystem with new gene expression solutions, enhanced multiplexing capabilities, and advanced automation. These additions aim to broaden dPCR adoption across molecular biology and biopharmaceutical applications, offering higher sensitivity and precision. The expansion includes new gene expression assays, improved cell and gene therapy quality control tools, and software enhancements for standardized analysis and reporting.
QIAGEN Expands QIAcuity Gene Expression Portfolio to Drive dPCR Use
QIAGEN has expanded its QIAcuity digital PCR (dPCR) ecosystem with new gene expression solutions, enhanced multiplexing capabilities, workflow automation, and standardized analysis tools. This expansion aims to accelerate dPCR adoption in research and biopharma by offering higher sensitivity, precision, and scalability. The company is set to launch new QIAcuity Gene Expression Assays and a high multiplex probe PCR kit, alongside software updates and automated solutions, positioning itself in the growing digital PCR market.
Qiagen strengthens QIAcuity gene expression portfolio
Qiagen has announced new additions to its QIAcuity digital PCR (dPCR) ecosystem to boost its gene expression capabilities, broaden assay content, and enhance workflow standardization. These updates aim to accelerate dPCR adoption in life sciences and biopharma by providing higher sensitivity, precision, and multiplexing capabilities. The company plans to introduce new QIAcuity Gene Expression Assays and QIAcuity OneStep High Multiplex Probe PCR Kit later in 2026, alongside QIAcuity Software 3.5 for advanced analysis and automated reporting.
QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma
QIAGEN has announced significant expansions to its QIAcuity digital PCR (dPCR) ecosystem, aiming to accelerate adoption in gene expression analysis across research and biopharma. New offerings include gene expression assays, high-multiplex probe PCR kits, and extended Cell and Gene Therapy quality control solutions. The updates also introduce enhanced workflow automation and standardized analysis capabilities with QIAcuity Software 3.5 and Hamilton integration, supporting widespread use of dPCR for higher sensitivity and precision.
